Slide 1: Investor Presentation Summer 2025
INVESTOR PRESENTATION Summer 2025
Slide 2: Legal Disclaimer
LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial
Slide 3: The Digital Platform for Doctors
THE DIGITAL PLATFORM FOR DOCTORS Leading Network Blue Chip Clients 80%+ 20/20 of all U.S. Top Hospitals Physicians1 and Health Systems Top Pharmaceutical Manufacturers3 >630K 118% Workflow Unique Net Revenue Active Providers2 Retention Rate4 1. As of 6/30/25. 2. For fiscal quarter ending 6/30/25. 3. T
Slide 4: Glaring Day-to-Day Inefficiencies
GLARING DAY-TO-DAY INEFFICIENCIES 70% of US HC communication still sent via fax1 75% of physicians attribute burnout to electronic health record (EHR) inefficiencies2 1. Konica Minolta, “New Facts About Fax in Healthcare,” 2023. 2. Tajirian et al., “The Influence of Electronic Health Record Use on Phy
Slide 5: Bringing Tech to Medicine
BRINGING TECH TO MEDICINE Inspired by enterprise tech Purpose-built for healthcare Networking Professional Network Professional Profiles, Search, Colleague Connectivity, Career Management News & Scheduling Newsfeed eSignatures Medical Articles & News, Peer Updates, Clinical Discussions, Sponsored Con
Slide 6: Purpose Built for Healthcare
PURPOSE BUILT FOR HEALTHCARE Professional Network Newsfeed Workflow InvestorPresentation Investor Presentation——August, May, 2025 2025
Slide 7: A Complete AI Suite for Clinicians
A COMPLETE AI SUITE FOR CLINICIANS A free, HIPAA- compliant suite of AI tools that is private to each clinician Scribe Write Answer Investor DOCS Presentation Investor Day —— August, June 2025 6, 2023
Slide 8: Strong Engagement
STRONG ENGAGEMENT News 1 Workflow 1 AI >1M QAU >630K QAU Prompts Up >5x y/y Investor Presentation - August 2025 1. QAU are unique quarterly active prescribers (MD/DO/NP/PA/Pharmacist/Med Student/CRNA)
Slide 9: Engagement Throughout the Day
ENGAGEMENT THROUGHOUT THE DAY 1 1. Doximity usage by prescribers (MD/DO/NP/PA/CRNA/Pharmacist/Med Student) in fiscal quarter ending 3/31/24. For News, darker shades represent higher activity on Doximity's Newsfeed. For Workflow, Investor Presentation — August, 2025 darker shades represent higher activ
Slide 10: Our Commercial Solutions
OUR COMMERCIAL SOLUTIONS Marketing Hiring Enterprise Workflow Educate on Latest News & Treatments Uncover Passive Candidates Reduce No-Shows & Leakage Relevance and personalization drive Rx’s & Referrals Find specialized talent #1 “Best in KLAS” Telehealth Video Conferencing Hundreds of thousands of
Slide 11: Marketing Solutions
MARKETING SOLUTIONS Largest Revenue Driver: Marketing Solutions Health Systems 2 17:1 ROI LexisNexis Pharma Leading Network Subscription Pricing Model >73% of healthcare spend 1. Audience (e.g. specialty) 3 is decided by Doctors1 2. Number of audience members > 11:1 ROI 3. Type and number of modules
Slide 12: Land & Expand Sales Motion
LAND & EXPAND SALES MOTION 1 Land Initial Brands or Service Lines 2 Expand to Add’l Brands or Service Lines Service Service Brand Line Line 07 07 08 Service Service Service Brand Brand Brand Line Line Line 04 05 06 04 05 06 Service Service Service Service Brand Brand Brand Brand Line Line Line Line
Slide 13: Core Newsfeed Modules
CORE NEWSFEED MODULES We create customized packages for customers Long Form Video Short Form Investor DOCS Presentation Investor Day —— August, June 2025 6, 2023
Slide 14: Workflow Modules
WORKFLOW MODULES Point of Care Formulary Investor DOCS Presentation Investor Day —— August, June 2025 6, 2023
Slide 15: Large & Growing Total Addressable Market
LARGE & GROWING TOTAL ADDRESSABLE MARKET + + (1) (2) (3) 1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDynamics and Kantar Media Intelligence, US Healthcare Ad Spend 2. Health System Marketing and Staf
Slide 16: Pharma Brand Opportunity
PHARMA BRAND OPPORTUNITY Our Penetration into Our Penetration into Estimated Share of HCP Marketing >$100M US Mega Brands1 <$100M US Mid Tier Brands2 Budget (all >$1m Brands)3 2% 1. As of March 31, 2025. # of brands with $100m+ in US sales (based on data from Evaluate Pharma) where Doximity has reve
Slide 17: Q1 Key Metrics
Q1 KEY METRICS LAND & EXPAND Number of Customers w/ $500K+ of Revenue1 Net Revenue Retention2 118% Total Company 120 $500K+ + 17% y/y Top 20 Customers 119% 1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than $500,000. 2. Refer to appendix for
Slide 18: Attractive Revenue Growth & Margin Profile
ATTRACTIVE REVENUE GROWTH & MARGIN PROFILE Revenue1 Adj. EBITDA & Margin1,2 55% 25% 40% CAGR CAGR 55% 48% 44% 44% 44% 31% 3 3 1. Fiscal Year ended March 31. 2. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA margin. Investor Presentation — Augus
Slide 19: Founder-Led, Mission Driven
FOUNDER-LED, MISSION DRIVEN 840 Jeff Tangney Anna Bryson EMPLOYEES1 CEO & Co-Founder CFO 1/3+ Lisa Greenbaum Jey Balachandran Amit Phull, MD CCO CTO Chief Clinical Experience Officer IN R&D1 Ben Greenberg Joel Davis Jennifer Chaloemtiarana SVP Commercial Products SVP Product General Counsel 1 As of J
Slide 20: Company Highlights
COMPANY HIGHLIGHTS 1 Leading digital platform for doctors 2 Powerful network effects 3 Sustainable revenue growth & profitability 4 Veteran vertical team 5 Massive near-term market opportunity fueled by shift to digital Investor Presentation — August, 2025
Slide 21: Appendix: Non-GAAP Financial Measures
APPENDIX: NON-GAAP FINANCIAL MEASURES To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance: Non-GAAP g
Slide 22: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation
APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION Year Ended March 31, TTM 2021 2022 2023 2024 2025 Q1 FY26 (in thousands) Net Income $50,210 $154,783 $112,818 $147,582 $223,185 $235,128 Adjustments: Acquisition and other related expenses 496 254 30 ‒ ‒ 428 Stock-based compensation 7,252 31